Loss of MXD3 induces apoptosis of Reh human precursor B acute lymphoblastic leukemia cells

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 4, 2015, Pages 329-335

  Barisone, Gustavo A ^a   Satake, Noriko ^a   Lewis, Carly ^a   Duong, Connie ^a   Chen, Cathy ^a   Lam, Kit S ^a   Nolta, Jan ^a   Díaz, Elva ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; MXD3; Precursor B acute lymphoblastic leukemia; Proliferation

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MXD3; UNCLASSIFIED DRUG; MXD3 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE; PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; STEM CELL MOBILIZATION; CASE CONTROL STUDY; CELL CYCLE CHECKPOINT; CYTOLOGY; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; MEDULLOBLASTOMA; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MEDULLOBLASTOMA; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRESSOR PROTEINS;

EID: 84961326624     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.12.002     Document Type: Article

References (21)

1. Pui C.H., et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012, 120(6):1165-1174.
2. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371(9617):1030-1043.
3. Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cells Mol. Dis. 2003, 31(1):84-92.
4. Robison L.L. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20years of age. Hematol. Am. Soc. Hematol. Educ. Program. 2011, 2011:238-242.
5. Ribera J.M. Advances in acute lymphoblastic leukemia in adults. Curr. Opin. Oncol. 2011, 23(6):692-699.
6. Hurlin P.J., et al. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. Embo J. 1995, 14(22):5646-5659.
7. Ayer D.E., Kretzner L., Eisenman R.N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993, 72(2):211-222.
8. Ayer D.E., Lawrence Q.A., Eisenman R.N. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 1995, 80(5):767-776.
9. Ayer D.E., Eisenman R.N. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev. 1993, 7(11):2110-2119.
10. Eisenman R.N.E. The Myc/Max/Mad transcription factor network. Current Topics in Microbiology and Immunology 2006, vol. 302. Springer, Berlin.
11. Foley K.P., et al. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. Embo J. 1998, 17(3):774-785.
12. Grandori C., et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 2000, 16:653-699.
13. Queva C., et al. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 1998, 16(8):967-977.
14. Fox E.J., Wright S.C. S-phase-specific expression of the Mad3 gene in proliferating and differentiating cells. Biochem. J. 2001, 359(Pt 2):361-367.
15. Barisone G.A., Yun J.S., Diaz E. From cerebellar proliferation to tumorigenesis: new insights into the role of Mad3. Cell Cycle 2008, 7(4):423-427.
16. Diaz E., et al. Molecular analysis of gene expression in the developing pontocerebellar projection system. Neuron 2002, 36(3):417-434.
17. Yun J.S., et al. A novel role of the Mad family member Mad3 in cerebellar granule neuron precursor proliferation. Mol. Cell. Biol. 2007, 27(23):8178-8189.
18. Barisone G.A., et al. Role of MXD3 in proliferation of DAOY human medulloblastoma cells. PLoS ONE 2012, 7(7):e38508.
19. Queva C., et al. Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol. Cell. Biol. 2001, 21(3):703-712.
20. Gore Y., et al. Mad3 negatively regulates B cell differentiation in the spleen by inducing Id2 expression. Mol. Biol. Cell 2010, 21(11):1864-1871.
21. Satake N., et al. Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 2014, 167(4):487-499.